Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of B7-H4-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.
This competitive intelligence report about B7-H4-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting B7-H4. The report lists B7-H4-targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of B7-H4-targeted immunotherapies by drug modality.
The B7-H4 surface antigen is overexpressed in ovarian and endometrial cancers and is often associated with poor prognosis. B7-H4 is a member of the B7 family of immune checkpoint ligands and has been shown to negatively regulate T-cell function. B7-H4 binds to an unknown receptor on T cells and inhibits T-cell proliferation and cytokine production.
B7-H4 expression is elevated across a broad range of solid tumors, including ovarian cancer, breast cancer, endometrial carcinoma, cholangiocarcinoma and gallbladder carcinoma, and squamous non-small cell lung cancer tumors. B7-H4 expression is limited in normal tissue, specifically immune cells, making it an ideal molecular target.
A number or antibody modality technologies were used to generate anti-B7-H4 drug candidates undergoing preclinical and clinical development, including antibody-drug conjugates, conditionally activated antibodies, T-cell engaging bispecific antibodies and other effector-enhanced antibody molecules.
For more information about this report visit https://www.researchandmarkets.com/r/yze396
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
